Zealand Pharma Partners with Roche and Unveils 2030 Strategy for Obesity Treatments

Zealand Pharma A/S reported its full-year 2025 financial results, highlighting a transformative collaboration and license agreement with Roche to develop petrelintide for weight management. This strategic partnership positions the company as a key player in the highly competitive obesity treatment market. Looking ahead, 2026 is expected to be a catalyst-rich year with critical Phase 2 data for petrelintide and Phase 3 results for survodutide. Furthermore, the company introduced its 'Metabolic Frontier 2030' strategy, which aims for five product launches and over 10 clinical programs by the end of the decade. This roadmap underscores Zealand Pharma's transition into a commercial-stage biotech leader leveraging AI-driven discovery. The combination of high-stakes clinical data and strategic alliances provides a strong bullish outlook for the company's long-term growth.